Sugi Predict

Sugi Predict / Compounds / SCHEMBL783771

SCHEMBL783771

SCHEMBL783771

O=S(=O)(c1ccccc1)n1ccc2c(Cl)ncnc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C19 P33261 1/20 0.51
▸ PKM P14618 1/20 0.45
▸ HTR6 P50406 13/20 0.44
▸ MET P08581 1/20 0.44
▸ MEN1 O00255 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ HTR1A P08908 1/20 0.40
▸ HTR1D P28221 1/20 0.40
▸ HTR1B P28222 1/20 0.40
▸ HTR1F P30939 1/20 0.40
▸ HTR7 P34969 1/20 0.40
▸ DRD3 P35462 1/20 0.40
▸ DRD2 P14416 1/20 0.39
▸ HTR2A P28223 1/20 0.39
▸ SLC22A12 Q96S37 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30752005 0.86 L3MBTL1 (0.52) CYP2C19PKMHTR6ALDH1A1HPGD
SCHEMBL1356181 0.86 L3MBTL1 (0.52) CYP2C19PKMHTR6ALDH1A1HPGD
SCHEMBL16049097 0.82 CYP2C19 (0.51) CYP2C19PKMHTR6METMEN1
SCHEMBL16271835 0.82 CYP2C19 (0.51) CYP2C19HTR6METMEN1ALDH1A1
SCHEMBL28212526 0.82 CYP2C19 (0.51) CYP2C19PKMHTR6METMEN1
SCHEMBL5010304 0.81 HTR6 (0.41) CYP2C19HTR6METSLC22A12
SCHEMBL29247906 0.81 RAPGEF4 (0.44) PKMMETALDH1A1TSHRHTT
SCHEMBL24401233 0.79 CYP2C19 (0.51) CYP2C19PKMHTR6METMEN1
SCHEMBL414843 0.79 CYP2C19 (0.58) CYP2C19PKMHTR6METMEN1
SCHEMBL3653359 0.79 CYP2C19 (0.51) CYP2C19PKMHTR6METMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4166557-B1 INTERMEDIATES OF N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES NOVARTIS AG (CH) 2026-05-06 — — EP disclosed
US-12441733-B2 Substituted 2,4-dioxotetrahydropyrimidines as intermediates in the synthesis of bruton's tyrosine kinase inhibitors NOVARTIS AG (CH) 2025-10-14 — — US disclosed
US-20250243207-A1 SYNTHETIC METHODS FOR PREPARING A PYRIDINECARBOXAMIDE COMPOUND BIOMEA FUSION, INC. 2025-07-31 — — US disclosed
US-20250243171-A1 QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE ARTHROSI THERAPEUTICS, INC. 2025-07-31 — — US disclosed
EP-4554937-A1 SYNTHETIC METHODS FOR PREPARING A PYRIDINECARBOXAMIDE COMPOUND Biomea Fusion, Inc. (US) 2025-05-21 — — EP disclosed
EP-4467549-A2 INTERMEDIATES OF N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES Novartis AG (CH) 2024-11-27 — — EP disclosed
CN-118754858-A N- (3- (7H-pyrrolo [2,3-d ] pyrimidin-4-yl) phenyl) benzamide derivatives 诺华股份有限公司 2024-10-11 — — CN disclosed
EP-4392423-A1 QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE Arthrosi Therapeutics, Inc. (US) 2024-07-03 — — EP disclosed
US-20240158399-A1 N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide Derivatives NOVARTIS AG (CH) 2024-05-16 — — US disclosed
CN-111936498-B N- (3- (7H-pyrrolo [2,3-d ] pyrimidin-4-yl) phenyl) benzamide derivatives 诺华股份有限公司 2024-04-16 — — CN disclosed
CN-1125070-C Pyrrolo [2,3-d] pyrmidine compounds PFIZER PROD INC (US) 2003-10-22 — — CN disclosed
US-6635762-B1 Protein tyrosine kinase or Janus Kinase 3 inhibitors; immunosuppressants PFIZER INC. 2003-10-21 — — US disclosed
US-6610847-B2 Tyrosine kinase inhibitors; immunosuppressants PFIZER INC. 2003-08-26 — — US disclosed
US-20020019526-A1 Pyrrolo[2,3-d]pyrimidine compounds PFIZER INC. 2002-02-14 — — US disclosed
CN-1305479-A Pyrrolo [2,3-d] pyrmidine compounds PFIZER PROD INC (US) 2001-07-25 — — CN disclosed
CN-1305480-A Pyrrolo [2, 3-d ] pyrimidine compounds PFIZER PROD INC (US) 2001-07-25 — — CN disclosed
EP-1087970-A1 PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS Pfizer Products Inc. (US) 2001-04-04 — — EP disclosed
EP-1087971-A1 PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS Pfizer Products Inc. (US) 2001-04-04 — — EP disclosed
WO-1999065908-A1 PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS PFIZER PRODUCTS INC. (US) 1999-12-23 — — WO disclosed
WO-1999065909-A1 PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS PFIZER PRODUCTS INC. (US) 1999-12-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158399-A1 N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide Derivatives PAH, REN, PKD1 CYP2C19 56/4885PKM 324/4885HTR6 1479/4885
US-20250243171-A1 QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE EGFR, ABL1, ERBB2 CYP2C19 399/4885PKM 4718/4885HTR6 1875/4885
US-20020019526-A1 Pyrrolo[2,3-d]pyrimidine compounds JAK1, JAK3, JAK2 CYP2C19 1984/4885PKM 1787/4885HTR6 4110/4885
US-12441733-B2 Substituted 2,4-dioxotetrahydropyrimidines as intermediates in the synthesis of bruton's tyrosine kinase inhibitors BTK, ABL1, LYN CYP2C19 542/4885PKM 1857/4885HTR6 2555/4885
US-20250243207-A1 SYNTHETIC METHODS FOR PREPARING A PYRIDINECARBOXAMIDE COMPOUND MLLT1, DOT1L, MEN1 CYP2C19 2460/4885PKM 2198/4885HTR6 3121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.